Immunoregulation and differentiation markers in monoclonal gammopathies.
Multiple myeloma and benign monoclonal gammopathies (BMG) are regarded as monoclonal B cell proliferations in which B lymphocyte maturation is blocked in the final stages of the differentiation cycle. Further studies with monoclonal antibodies (MoAbs) of the FMC series and of the 791T/36 MoAb will perhaps provide a final subclassification of the B lymphocyte proliferation diseases and hopefully assist in their diagnosis and treatment.
D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D002454:Cell Differentiation; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000145:classification* / Q000473:pathology; D009101:Multiple Myeloma / Q000276:immunology* / Q000473:pathology; D010265:Paraproteinemias / Q000145:classification / Q000276:immunology* / Q000473:pathology; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface